Glaalpha

• 

  Glaalpha package insert

  Scan the QR code linked to package insert.

  

• Glaalpha Combination Ophthalmic Solution is an ophthalmic agent for the treatment of glaucoma containing ripasudil hydrochloride hydrate (0.4%), a Rho kinase inhibitor, and brimonidine tartrate (0.1%), an α2 adrenoreceptor agonist, as active ingredients.

  Ripasudil hydrochloride hydrate demonstrates intraocular pressure-lowering effects by increasing conventional outflow via the trabecular meshwork and Schlemm's canal. Brimonidine tartrate demonstrates intraocular pressure-lowering effects by inhibition of aqueous humor production in the ciliary epithelium and increasing uveoscleral outflow based on α2 adrenoreceptor agonist activity.

  Glaalpha is the only novel fixed-dose combination (FDC) that has three mechanisms for lowering intraocular pressure in one formulation: increasing conventional outflow, increasing uveoscleral outflow, and inhibition of aqueous humor production.

  In conclusion, Glaalpha can contribute to improved adherence and expanded treatment options for patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to monotherapy.